Nobel Laureate Shinya Yamanaka, the first to produce induced pluripotent stem cells.
Induced pluripotent stem cells or IPS cells just might be the most exciting development in the stem cell field over the last 15 years.
They have unique potential for clinical impact for regenerative medicine too, both through their use to produce differentiated cellular therapies and indirectly via disease modeling as well as drug screening.
The scientist who first made them, Dr. Shinya Yamanaka, received the Nobel Prize in 2012 for this discovery. Dr. Yamanaka thought outside the box. He applied basic science knowledge gained over many years about early mammalian development, embryonic stem cells, and transcription factors.
But the story leading up to IPS cells really starts in the 1980s in part in Seattle. More below.
You might have noticed that here on The Niche we have the URL ipscell.com so when it comes to induced pluripotent stem cells, we know our stuff.
Weve been following the IPS cell research field for more than a decade and doing IPS cell research ourselves in the Knoepfler lab. You can see a microscopy image of colonies of human IPS cells that my lab produced years ago. We stained them in red for a human embryonic stem cell marker, which lights up human IPS cells too.
This post is an overview of IPS cells. It includes recommended resources about them since their first report in 2006 (mouse) and 2007 (human). Also, what are current and future prospects for clinical impact?
While mouse IPS cells were the first reported reprogrammed pluripotent stem cells by Yamanaka, one year later human versions were reported both by the initial discoverer Shinya Yamanaka and others including teams led by Jamie Thomson and Rudy Jaenisch.
IPS cells can be made from just about any normal type of cell, ranging from adult stem cells to cells that are not stem cells at all such as fibroblasts. In fact, fibroblasts are probably the most common type of cell changed into IPS cells.
How did scientists in the 2000s think that transcription factors might be able to reprogram cells?
There was a pioneering scientist named Harold (Hal) Weintraub at a place called the Fred Hutchinson Cancer Research Center (or as many of us call it affectionately for short The Hutch) in Seattle. You can read more about him here on the Hutch website.
Hal was definitely one of a kind and in a good way. I only met him once when I was a grad student at UCSD and had gone up to the Hutch to give a talk. I didnt know him, but when I did my postdoc at the Hutch I became very good friends with some of those who had known him well. Without exaggeration I can say they loved the guy and admired his work. I also knew Hals science well and was a big fan.
When I arrived at the Hutch in Bob Eisenmans lab to start my postdoc in 1998, people were still grieving Hals death 3 years earlier (see his NYT obithere). I also remember the moment I gave the sad news to my doctoral advisor, Mark Kamps, that Hal had passed away. For the first time in my years of working with Mark, he was visibly shaken. He thought the world of Hal and had interacted with him during a long running series of joint meetings between The Hutch and Salk scientists called the Salk-Seattle Meetings, which sadly no longer take place.
Hal was a visionary researcher in the area of transcription and cellular fate. He might have won the Nobel Prize and deservedly if he had not been taken from us by a brain tumor. At the same time Hal was the kind of scientist and person that I admire.
So, you might ask, why do I think Hal deserves some of the credit for the discovery of iPS cells?
He did pioneering studies of how genes influence cell fate. His models of how transcription factors direct cell fate were exemplified by his labs seminal work on MyoD, a powerful transcription factor that can induce a muscle cellular phenotype.
Hals labs first paper (see top portion above) reporting the existence of what would later be called MyoD for MYOblast Determination gene was truly revolutionary. His team reported the fact that introduction of a single defined factor, MyoD, induced fibroblasts to change into myoblasts that differentiate into myotubes. In fact MyoD sometimes reprogrammed even non-fibroblastic lineage cells into the muscle lineage. (note that a separate, but interesting question is whether some fibroblasts are actually functionally more like stem cells than we might assume).
So in the late 1980s Hal demonstrated a defined factor could induce direct reprogramming of cell fate. This is reminiscent of reprogramming to an IPS cell state.
The Weintraub lab papers from1987and1988more fully fleshed out the MyoD story.
In a perspectives piece, Yamanaka himself also attributes some of the credit in the pre-history of iPS cells to Hal Weintraub and I admire Yamanaka for that.
The definition of induced pluripotent stem cells is pluripotent stem cells that are made from non-pluripotent stem cells. They behave as though they are embryonic stem cells, but no embryo is needed.
The process by which IPS cells are produced is called reprogramming.
Whats that?
It essentially means the starting non-pluripotent stem cells like fibroblasts are recoded gene-expression and epigenetic-wise to think they are pluripotent stem cells like embryonic stem cells. Yamanaka used 4 defined factors (OCT4, SOX2, KLF4, and MYC) to complete the reprogramming of human dermal fibroblasts into human IPS cells.
Other groups used similar cocktails sometimes with slightly different combos. The key is that theses factors are fundamental embryonic control switches that tell cells to behave as though they are in the early embryo. You can see a Waddington model of how non-pluripotent stem cells are pushed back up the hill to a pluripotent state during reprogramming.
A tricky part of reprogramming is delivering these factors into the starting cells. Most often for research purposes retroviruses are used to transduce the starting cells with the defined factors. For clinical purposes other non-genetic methods are more commonly used such as transient introduction of non-integrating viruses coding the reprogramming factors or introduction of RNAs or the proteins themselves.
It took a while after their initial report in human form in 2007 to get to clinical trials using differentiated cells made from the IPS cells, but we are now in that exciting phase of this still relatively new field.
You can see my talk at the Future of Genomic Medicine meeting where I give an overview of some of the more exciting applications of IPS cells a few years back. These include actual clinical trials but also disease and developmental modeling. One of the more exciting areas for the latter are human brain organoids made from IPS cells.
In terms of actual clinical trials you can see this overview by my intern Suhas here that also cites some useful papers.
In terms of clinical trials, the pioneering work of Masayo Takahashifor macular degeneration got things going. Now more clinical trials are ongoing.
An articlepublished inNPJ Regenerative Medicine categorizes the PSC clinical trials found on Clinicaltrials.gov. The NPJ Regenerative Medicine report focused on a subset of 131 studies, finding that the majority of them, 77.1%, were observational and did not include the transplantation of any PSC into patients. The remaining 22.9% were interventional.
A search now in 2021 found 129 Clinicaltrials.gov listings related to induced pluripotent stem cells. You can see a clinical trials map above from the database. Note that Japan, while not having that many listings, has a higher % of actual interventional clinical trials.
Several biotech companies are engaged in clinical work with IPS cells including Cynata and Fate Therapeutics, just to name two.
I predict a few more interventional IPS cell clinical trials are going to pop up soon.
Well continue to see big impact as well from disease modeling and drug screening applications.
A big question is whether for actual interventional trials where IPS cell derivatives are injected into patients, will allogeneic (other peoples cells) or autologous (your cells) will dominate.
In any case, induced pluripotent stem cells have a big future including for personalized medicine.
Related Posts
Read more from the original source:
What are induced pluripotent stem cells or IPS cells ...
- Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing ... - PR Newswire - April 24th, 2024
- SCG CELL THERAPY AND A*STAR LAUNCH JOINT LABS WITH COLLABORATION NEARING S$30 MILLION TO ... - PR Newswire - April 20th, 2024
- Detection of biomagnetic signals from induced pluripotent stem cell-derived cardiomyocytes using deep learning with ... - Nature.com - April 1st, 2024
- Researchers discover new microRNA-regulated pathway to boost iPS cell-derived platelet production - Phys.org - March 30th, 2024
- Standardized production of hPSC-derived cardiomyocyte aggregates in stirred spinner flasks - Nature.com - March 28th, 2024
- Synthetic Circuits Reveal the Key to Rewinding the Cellular Clock - The Scientist - March 13th, 2024
- synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy - Nature.com - March 3rd, 2024
- Breaking through new research barriers with iPSC technology - News-Medical.Net - February 15th, 2024
- Abu Dhabi Stem Cells Centre partners with Rege Nephro and Kyoto University's Center for iPS Cell Research and ... - Abu Dhabi Media Office - January 12th, 2024
- Abu Dhabi Stem Cells Center partners with Japan-based Kyoto University and Rege Nephro - ZAWYA - January 12th, 2024
- Efficient and reproducible generation of human induced pluripotent stem cell-derived expandable liver organoids for ... - Nature.com - December 23rd, 2023
- Mechanisms, pathways and strategies for rejuvenation through epigenetic reprogramming - Nature.com - December 15th, 2023
- Shinobi Therapeutics Launches with Completion of $51M Series A to Advance Hypoimmune iPS-T Cell Therapy Platform - PR Newswire - December 13th, 2023
- CRISPRi gene modulation and all-optical electrophysiology in post-differentiated human iPSC-cardiomyocytes ... - Nature.com - December 7th, 2023
- World Hindu Congress 2023: Know all about the sessions and speakers - Organiser - November 23rd, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS ... - Business Wire - November 21st, 2023
- Efficient protocol for the differentiation of kidney podocytes from ... - Nature.com - November 17th, 2023
- Vitamin B12 is a limiting factor for induced cellular plasticity and ... - Nature.com - November 17th, 2023
- Study reveals the critical role of microglia in human brain development - Medical Xpress - November 15th, 2023
- VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600 million Japanese yen (approximately $4 million USD) through... - November 15th, 2023
- Who are the leading innovators in iPSCs for the pharmaceutical ... - Pharmaceutical Technology - November 7th, 2023
- Using iPS Cells from I Peace, Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes, A Major Step Forward in Advancing Autologous... - November 5th, 2023
- Systematic differences in discovery of genetic effects on gene ... - Nature.com - October 21st, 2023
- Pairwise biosynthesis of ion channels stabilizes excitability and ... - pnas.org - October 11th, 2023
- Scientists find multitude of genes associated with autism - The Statesman - October 9th, 2023
- Stem Cell Banking Market is Expected to Reach USD 16,474.30 ... - Digital Journal - October 7th, 2023
- Probing the individuality of cells and molecules - Open Access Government - October 5th, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Manchestertimes - October 3rd, 2023
- Thymmune Therapeutics Receives $37M in Funding from the ... - Business Wire - September 29th, 2023
- Less Funding to More Researchers Gets Nobel-level Results, Study ... - The Japan News - September 27th, 2023
- Brentuximab Vedotin Plus AVD Gets Positive CHMP Opinion for ... - OncLive - September 20th, 2023
- DKMS BMST Foundation India and Kokilaben Hospital unite to spread awareness about the Importance of Stem Cell Donation on World Marrow Donor Day - APN... - September 18th, 2023
- Vitamin B6 is governed by the local compartmentalization of ... - Science - September 14th, 2023
- Dolly the sheep creator Ian Wilmut dies aged 79 - BBC - September 14th, 2023
- Scientist who created Dolly the sheep dies aged 79: Professor Sir Ian Wilmut passes away five years after reve - Daily Mail - September 11th, 2023
- The global kits market is expected to grow at a CAGR of 7.4% from ... - Digital Journal - September 8th, 2023
- Eterna Therapeutics Announces Initiation of Development Activities ... - PipelineReview.com - September 8th, 2023
- Tokyo: 100 Years of Urban Regeneration / Tokyo's Nihonbashi Area ... - The Japan News - August 31st, 2023
- Transcriptome-based prediction of drugs, inhibiting ... - Nature.com - August 30th, 2023
- From the birds and the bees to IVG - The Gauntlet - August 26th, 2023
- Breakthrough creates stem cells without any memories - Freethink - August 26th, 2023
- Aging impairs the neurovascular interface in the heart - Science - August 26th, 2023
- For This Venture Capitalist, Research on Aging Is Personal; 'Bob ... - The Wall Street Journal - August 22nd, 2023
- Unleashing Potential: Illuminating the Future of Healthcare through Revolutionary Induced Pluripotent Stem Cel - openPR - August 18th, 2023
- A 'memory wipe' for stem cells may be the key to better therapies - The Conversation - August 16th, 2023
- Erasing epigenetic 'memory' to improve the quality of stem cells - FierceBiotech - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Business Wire - August 16th, 2023
- HebeCell and Logomix Announce Collaboration for the ... - Valdosta Daily Times - August 11th, 2023
- Advancing Clinical Trials with iPSC-Derived Liver Organoids - Microbioz India - August 11th, 2023
- Activation of cAMP (EPAC2) signaling pathway promotes hepatocyte ... - Nature.com - August 1st, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of Aging Damage Reversal Showing GIVI-MPC Stem Cell Therapys Ability to Create New Skeletal... - July 30th, 2023
- Femtech in Japan: An Industry on the Rise - Femtech Insider - July 28th, 2023
- Association between enhanced carbonyl stress and decreased ... - Nature.com - July 28th, 2023
- Defects in early synaptic formation and neuronal function in Prader ... - Nature.com - July 27th, 2023
- IPS HEART Announces Peer-Reviewed Publication in Cells of ... - Business Wire - July 25th, 2023
- Cure to Autism and Alzheimer's May Be in Space, Says 1st Brazilian Scientist who Will Be on The ISS - Folha de S.Paulo - July 25th, 2023
- Futurama's Resurrection Ruins The Perfect Ending (& Shows Must ... - Looper - July 25th, 2023
- University Of Massachusetts Amherst's Team Bags Honour Of 2023 Armstrong Fund For Science Award - India Education Diary - July 20th, 2023
- Scientists working on IVG, a new reproductive method that can make human babies in labs - IndiaTimes - July 19th, 2023
- Co-transplantation of autologous Treg cells in a cell therapy for ... - Nature.com - July 13th, 2023
- Magic Valley and Biocellion Join Forces to Improve Bioreactor Tech ... - vegconomist - the vegan business magazine - July 13th, 2023
- IPS HEART Receives U.S. FDA Rare Pediatric Drug Designation for ... - Tullahoma News and Guardian - July 10th, 2023
- Hitachi : forms strategic research collaboration with Mass General Brigham in the field of regenerative medicine and GCT - Marketscreener.com - July 6th, 2023
- Cell therapy limitations with iPS-based multi-cell therapeutics - Drug Target Review - July 6th, 2023
- Remembering Dolly- The Clone Sheep On Her Birth Anniversary - Free Press Journal - July 4th, 2023
- Labs and Translational Research - UMass Medical School - June 28th, 2023
- Cellusion raises 2.83B series C round to progress iPS cell-derived ... - BioWorld Online - June 14th, 2023
- Japan-based Fujifilm introduces first-of-its-kind human iPSC-derived ... - BSA bureau - June 6th, 2023
- ALS: Parkinson's drug ropinirole may be an effective treatment - Medical News Today - June 4th, 2023
- Scientists predict lab-grown babies in five years - Kidspot - June 4th, 2023
- Lab-grown babies could become a reality within five years - Earth.com - May 26th, 2023
- Leading healthcare experts from MENA and beyond to explore the future of precision medicine in the region at PMES 23 this month - ZAWYA - May 24th, 2023
- Long-Awaited Ax-2 Mission Launches, Heads to Space Station - AmericaSpace - May 22nd, 2023
- Eterna Therapeutics and Factor Bioscience Announce New Data on ... - GlobeNewswire - May 17th, 2023
- Research Assistant job with UNITED ARAB EMIRATES ... - Times Higher Education - May 10th, 2023
- Regulation of synaptic connectivity in schizophrenia spectrum by ... - Nature.com - April 29th, 2023
- Researchers Discover Key Role of Glucose in Brain Activity - Laboratory Equipment - April 25th, 2023
- Structure of Huntington's Protein Revealed - Technology Networks - April 21st, 2023
- Study of brain immune cell infection may explain long COVID ... - NHK WORLD - April 19th, 2023
- The Mechanism That Regulates Activity of Memory Gene - Neuroscience News - April 19th, 2023
Recent Comments